Oral Solid Dosage Contract Manufacturing Market Size, Share, Trends & Forecast, 2026–2034
REPORT DETAILS
Oral Solid Dosage Contract Manufacturing Market Summary
Oral Solid Dosage Contract Manufacturing Market size was valued at USD 10.07 billion in 2025. The market is anticipated to grow from USD 10.99 billion in 2026 to USD 22.62 billion by 2034, exhibiting a CAGR of 9.4% during the forecast period.
Market Statistics
Oral Solid Dosage Contract Manufacturing Market Key Takeaways
- Asia-Pacific is expected to witness the fastest growth during the forecast period with 11.80%. The region’s dominance can be attributed to strong manufacturing capacity and increasing pharmaceutical outsourcing.
- North America accounted for 41.20% of the global market revenue in 2025. The growth can be attributed to rising investment in drug development and clinical research.
- Capsules segment is expected to grow at a CAGR of 10.80% during 2026–2034. Capsules are easy to use and provide faster drug release making them a preferred dosage form.
- Controlled release captured 43.50% market revenue in 2025. The need for consistent and long-lasting drug delivery is a key factor responsible for the sustained demand.
- Large enterprises are projected to grow at a CAGR of 8.70% during 2026–2034. To improve efficiency and quality many pharmaceutical companies continue to outsource production.
- Tablets represented 33.10% of the market revenue in 2025. Their low manufacturing cost and widespread use continue to support demand.
Note: Figures and projections outlined in this report are the result of Polaris Market Research’s proprietary analytical processes, grounded in the latest available datasets and market observations.
What Is Oral Solid Dosage Contract Manufacturing?
Oral solid dosage (OSD) contract manufacturing involves the outsourced production of oral medicines by a third-party company. Oral medicines include tablets, capsules, powders, and granules. A contract manufacturer can fulfilll manufacturing, packaging, testing, and other production requirements.
A Contract Manufacturing Organization (CMO) is essentially a service provider for manufacturing. A Contract Development and Manufacturing Organization (CDMO) is a service provider for both development and manufacturing. Pharmaceutical companies use these services to reduce costs, increase production capacity and get medicines to market faster.
How Oral Solid Dosage Contract Manufacturing Works
To ensure consistent quality and regulatory compliance oral solid dosage contract manufacturing follows a structured production process. The formulation development initiates the process. The active pharmaceutical ingredient (API) and other raw materials required for the product are selected by the manufacturer. The formulation is tested and modified to obtain the required quality and performance.
After this, the materials are mixed together. Granulation may be carried out to improve the quality of the mixture. The prepared material is then used to make tablets or fill capsules. Some medicines also need a coating. The coating may protect the tablet or may control release of the drug.
The finished products are tested for quality. Tests are performed to confirm the drug’s strength, quality and purity. When the product successfully completes all the required tests, it is packaged and labeled. The product can be serialized to track it during distribution. The finished drugs are then sent to pharmacies, hospitals and other health-care providers.
Market Introduction
Active pharmaceutical ingredients (APIs) have become more complex over time, leading to a number of creative formulations that help carry drugs to their target sites of action efficiently. Even with these developments, there is still an unmatched need for oral solid dose (OSD) forms like tablets and capsules. It has been noted that almost two-thirds of prescription medications worldwide are given as oral solids. In addition to being more affordable and having more stability than their bigger molecule equivalents, these tiny molecules that are taken orally put the needs of the patient first and are essential in helping to overcome problems with drug adherence.
As a result of the increased emphasis on regulatory compliance, there are opportunities in the Oral Solid Dosage (OSD) Contract Manufacturing market. Companies are searching for contract manufacturers with a track record of compliance as the pharmaceutical industry struggles with complex regulatory environments. OSD contract manufacturers now have the chance to set themselves apart by making investments in quality management systems, putting in place reliable documentation procedures, and abiding by global regulatory norms.
Source: Polaris Market Research Analysis
To Understand More About this Research: Download Sample Report
- For instance, in August 2025, to expand oral solid dosage capabilities Piramal Pharma Solutions and NewAmsterdam Pharma invested in a dedicated facility. The facility will help the development and manufacturing of oral solid dosage products.
The oral solid dosage contract manufacturing market growth can be credited to advancements in drug delivery technology, encompassing targeted drug delivery and sustained-release dosage forms. Additionally, investments by contract development manufacturing organizations to broaden oral solid dosage development and the rising demand for innovative therapies contribute to this trend.
Market Dynamics
Market Driver- Rising Pharmaceutical Outsourcing
Pharmaceutical companies are turning to CDMOs for drug development and manufacturing support. This supports them use existing facilities and reduce the need for new production sites. For example, in February 2025, Recipharm opened a new pilot-scale development center in Germany. The center can produce GMP pilot-scale blends, granules, tablets, and hard capsules. The investment also includes clinical supplies, technology transfers and small-batch manufacturing (Source: recipharm.com).
Market Driver- Generic Drug Demand & Patent Expirations
The demand for generic medicines is creating more need for tablet and capsule manufacturing. CDMOs can help drug companies produce these medicines at different production levels. For example, Acme Generics has reported an annual capacity of 17 billion tablets and 3 billion capsules across its manufacturing operations. The company also provides contract manufacturing and development services for Indian and global pharmaceutical companies. This supports the increasing need for large scale OSD production (Source: acmegenerics.in)
Market Opportunity- Advances in Drug Delivery & Complex Formulations
New oral formulations are creating opportunities for CDMOs with advanced manufacturing skills. Recipharm’s pilot plant, opened in 2025, can make both single- and dual-fill capsules and advanced tablet making, and its equipment supports dry and wet granulation, capabilities that can help drug companies develop products with more complex formulations. They also allow CDMOs to support projects from early development through small-scale commercial production (Source: recipharm.com).
Market Opportunity- Supply-Chain Resilience & Localization
Building production capacity in different regions can help pharmaceutical companies reduce supply risks. In August 2025, Piramal Pharma Solutions and NewAmsterdam Pharma opened a dedicated OSD suite in Pennsylvania. The multi-million-dollar investment supports fixed dose combination products and includes granulation, compression, tableting, and coating capabilities. Through its facilities in India Piramal also provides dual sourcing support. This setup gives customers more options for production and supply (Source: biospectrumindia.com).
Market Restraint- Regulatory & Quality Challenges
Following different quality and regulatory requirements can be difficult for OSD manufacturers. Different markets may require different testing, documentation, validation and product release rules. Manufacturers also need to keep processes the same from batch to batch. Changes in materials or process steps may require additional checks, adding time and cost to the manufacturing process.
OSD Contract Manufacturing Services
OSD contract manufacturers provide services that support pharmaceutical companies from product development to production. These services include formulation development, process development, scale up, and technology transfer. Based on the product requirements manufacturers may also handle granulation, tablet compression, capsule filling, and coating.
Packaging and labeling are also part of OSD contract manufacturing services. Manufacturers carry out quality testing to check whether the products meet the required standards. Some CDMOs also provide regulatory and quality support for different markets. These services provide pharmaceutical companies the opportunity to leverage specialized facilities and manufacturing expertise. They don’t have to do every step themselves.
In-House Manufacturing vs Contract Manufacturing
| Feature | In-House Manufacturing | Contract Manufacturing |
| Capital Investment | High | Lower |
| Manufacturing Expertise | Internal | Specialized |
| Scalability | Limited | High |
| Regulatory Support | Internal | Extensive |
| Time-to-Market | Longer | Faster |
| Operational Flexibility | Moderate | High |
Source: Polaris Market Research Analysis
Source: Polaris Market Research Analysis
Report Segmentation
The market is primarily segmented based on product, mechanism, end-user, and region.
| By Product | By Mechanism | By End-User | By Region |
|
|
|
|
Source: Polaris Market Research Analysis
By Product Analysis
The tablets segment accounted for 33.10% of revenue in 2025. It remained the leading product segment. Tablets are widely used across different types of medicines. Their established manufacturing process and large production volumes continue to support demand. Granules, powders, and other products also contribute to the market.
The capsules segment is expected to grow at a CAGR of 10.80% during the forecast period. After this continue with existing content. The increasing benefits associated with capsules, including ease of swallowing, rapid disintegration, and absorption, are anticipated to propel the market forward. These capsules exhibit faster disintegration, facilitating the swift release and absorption of medication. Additionally, the market is expected to experience growth driven by technological advancements and the widespread adoption of such innovations to enhance capsule-filling capabilities.
By Mechanism Analysis
In 2025, the controlled release segment held a 43.50% market share. It was the leading mechanism in the oral solid dosage contract manufacturing market. This drug delivery mechanism sustains a steady drug concentration in tissues and the bloodstream for an extended period. Recent progress in oral controlled-release (CR) delivery systems, encompassing innovations like intestinal patches, polymer nanosystems, dome tablets, dual drug tablets, and bioinspired delivery methods such as exosomes, has brought about a transformative shift in the field.
The immediate release segment is expected to grow at a CAGR of 8.50% during the forecast period. These medicines release the active ingredient soon after administration. They are widely used for treatments that need quick action. Their simple production process also supports demand from pharmaceutical manufacturers. Delayed release serves specific drug needs.
Product / Mechanism Comparison
| Segment | Typical Example | Core Advantage | Manufacturing Consideration |
| Tablets | Compressed and coated tablets | Easy to produce at scale and widely used | Compression, coating, and uniform mixing |
| Capsules | Hard capsules and special capsule fills | Easy to use and flexible for different formulations | Capsule filling and powder or granule flow |
| Granules | Granulated oral products | Better flow and easier dose handling | Granulation and drying |
| Powders | Oral powders and sachets | Flexible for different formulations | Mixing, moisture control, and packaging |
| Immediate Release | Conventional-release products | Releases the drug quickly | Disintegration and dissolution control |
| Controlled Release | Extended- and sustained-release products | Can reduce dosing frequency | Polymer systems and release testing |
| Delayed Release | Enteric and delayed-release products | Releases the drug at a specific stage | Coating and dissolution control |
Source: Polaris Market Research Analysis
By End-User Analysis
Large enterprises are expected to grow at a CAGR of 8.70% during the forecast period. The segment is expected to remain a key end-user group in the market. After this add existing content. Prominent pharmaceutical corporations opt to subcontract the formulation and manufacturing of oral solid dose medications, citing quality and reliability as their foremost considerations. However, beyond these priorities, their preferences diverge. Established pharmaceutical entities prioritize productivity as the second most crucial factor, succeeded by considerations for affordability, innovation, and adherence to regulatory standards. In contrast, Contract Manufacturing Organizations (CMOs) that specialize in oral solid dosage offer numerous advantages to large pharmaceutical companies, contributing to a growing trend of adoption.SMEs accounted for 34.70% of market revenue in 2025. These companies often outsource OSD manufacturing to access specialized facilities and production expertise. This helps them manage manufacturing needs without major investment in their own facilities.
Source: Polaris Market Research Analysis
Regional Insights
Asia-Pacific region dominated the global oral solid dosage contract manufacturing market study in 2026
In 2025, Asia-Pacific held 23.80% of the global market revenue. It led the market and is expected to continue to hold the leading position. The surge in growth can be attributed to various factors, including enhanced social insurance schemes and continually improving economic conditions in the region. These improvements enable patients to bear pharmaceutical costs out-of-pocket. Notably, countries such as India, China, and Singapore have emerged as significant players in the pharmaceutical industry due to their expanding capabilities in the oral solid dosage contract manufacturing process. Over the past decade, there has been a notable trend of outsourcing the manufacturing of pharmaceutical products to Asian countries, particularly India and China.
North America is expected to be the fastest-growing region in the oral solid dosage contract manufacturing market
North America is expected to account for 41.20% of the market revenue during the forecast period. The need for oral solid dosage contract manufacturing is being driven by pharmaceutical companies' growing investments in the research and development of new medications. One important element driving the market's growth is the expansion of the pharmaceutical business in the U.S. and Canada. Further driving market expansion is anticipated to come from the current clinical trials as well as the active involvement of major market participants.
Europe held a strong position in the oral solid dosage contract manufacturing market
Europe continues to have steady demand for OSD contract manufacturing services. Germany and the U.K. have established pharmaceutical industries and support a wide range of drug manufacturing activities. The stringent EU-GMP standards also motivate companies to partner with manufacturers that can meet high quality and production standards.
Latin America’s rising need for contract manufacturing of oral solid dosage products
Contract manufacturing in the pharmaceutical industry is gaining popularity in Latin America. Local pharmaceutical companies may utilize contract manufacturing to gain access to manufacturing facilities and technical knowledge. This can also assist companies in increasing local capacity and fulfilling the growing need for oral solid dosage products.
Middle East & Africa is seeing gradual growth in oral solid dosage contract manufacturing
Pharmaceutical companies in the region are working to increase local drug production. Contract manufacturers can help by providing production facilities and technical support. The need to build new facilities can be reduce with this. It can also help address local demand for tablets, capsules and other oral drugs.
Use Cases of Oral Solid Dosage Contract Manufacturing
| Use Case | Application |
| Generic tablet manufacturing | Production of cost-effective generic medicines |
| Capsule production services | Manufacturing hard and soft capsule formulations |
| Controlled-release drug manufacturing | Production of medicines with sustained drug release |
| Nutraceutical tablet production | Manufacturing vitamins, minerals, and dietary supplements |
| Clinical trial supply manufacturing | Production of medicines for clinical studies |
| Commercial drug production | Large-scale manufacturing for market supply |
| High-potency oral drug manufacturing | Production of medicines requiring specialized containment |
| Pediatric oral dosage development | Manufacturing child-friendly oral formulations |
| Pharmaceutical packaging services | Packaging, labeling, and serialization of medicines |
| Global drug supply chain support | Manufacturing and distribution for international markets |
Source: Polaris Market Research Analysis
Technology Trends in OSD Contract Manufacturing
How oral solid dosage products are developed and manufactured is changing with technology. Contract manufacturers are using new systems to improve production speed, product quality, and process control. Continuous manufacturing can support reduce production time and improve process consistency. Process analytical technology (PAT) also allows manufacturers to monitor critical steps in the production process in real time. Complex coating systems are used for products that require controlled drug release or to provide additional protection. Automation can reduce manual labor and allow for consistent production. Digital instruments are also enabling manufacturers to manage quality data and production records. These are useful for pharmaceutical companies that seek reliable production and increased control over the manufacturing processes.
Continuous Manufacturing
Continuous manufacturing allows materials to flow through various stages of production with less interruption. This can improve process control and reduce the time required for production. It can be useful for OSD products that require steady and consistent output. To support efficient production and improve manufacturing capacity contract manufacturers can use this approach.
High-Potency OSD Containment
In manufacturing high-potency medicines need careful handling. Contract manufacturers need to have the right containment systems in place, to protect the workers and prevent cross contamination, which might include dedicated areas, controlled equipment and proper handling procedures. Companies that are developing high potency OSD products may want to partner with CDMOs that have the right facilities and containment capabilities.
Artificial Intelligence, Automation & Digital Quality
Artificial intelligence and automation are being applied in real world OSD manufacturing situations. Digital systems can be used by manufacturers to track production data and identify process issues. Predictive tools can also help with equipment maintenance and process planning. Digital batch records can reduce paperwork and improve access to production information. Real time monitoring can also help with quality checks during production.
Key Market Players & Competitive Insights
Keep existing content and add below content after existing content: These players focus on partnership, product upgrades, and collaboration to gain a competitive edge over their peers and capture a significant market share.
Aenova Group is a major CDMO for oral solid dosage products. It operates multiple manufacturing and development sites across Europe and the U.S. The company offers tablet and capsule development, manufacturing, packaging, and supply services. Its oral solids network has annual capacity of more than 22 billion tablets and capsules.
Some of the major players operating in the global market include
Piramal Pharma Solutions provides development and manufacturing services for oral solid dosage products. In 2025, it opened a dedicated OSD suite at its Pennsylvania facility. The site supports granulation, compression, tableting, and coating for fixed-dose combination products.
Source: Polaris Market Research Analysis
Some of the major players operating in the global market include
- AbbVie Contract Manufacturing
- Aenova Group
- Alkem Laboratories Limited
- Catalent, Inc.
- Reddy's Laboratories
- Evonik
- Famar
- Granules India Limited
- Jubilant Pharmova Limited
- Lonza
- Patheon Pharma Services (Thermo Fisher Scientific)
- Pfizer CentreOne
- Piramal Pharma Solutions
- Recipharm AB
- Vetter Pharma
Vendor Positioning Framework
| Company | Positioning |
| AbbVie Contract Manufacturing | Provides contract manufacturing services supported by pharmaceutical manufacturing facilities. |
| Aenova Group | Focuses on pharmaceutical development and large-scale contract manufacturing. |
| Alkem Laboratories Limited | Focuses on generic medicines, formulations, and pharmaceutical manufacturing. |
| Catalent, Inc. | Provides oral dosage manufacturing and drug delivery services. |
| Dr. Reddy's Laboratories | Has large-scale generic drug manufacturing and formulation capabilities. |
| Evonik | Provides pharmaceutical manufacturing and development services, including drug delivery solutions. |
| Famar | Provides pharmaceutical development, manufacturing, and packaging services. |
| Granules India Limited | Focuses on pharmaceutical manufacturing, including active ingredients and finished dosage products. |
| Jubilant Pharmova Limited | Offers pharmaceutical manufacturing and CDMO services, including OSD capabilities. |
| Lonza | Offers small-molecule and dosage-form development and manufacturing services. |
| Patheon Pharma Services (Thermo Fisher Scientific) | Provides drug product development and commercial manufacturing through a global CDMO network. |
| Pfizer CentreOne | Provides contract manufacturing and pharmaceutical supply services. |
| Piramal Pharma Solutions | Offers integrated development and manufacturing services with OSD capabilities. |
| Recipharm AB | Provides pharmaceutical development and commercial manufacturing services. |
| Vetter Pharma | Provides pharmaceutical manufacturing and packaging services, including oral dosage capabilities. |
Source: Polaris Market Research Analysis
Recent Developments
- March 2026: Forma Life Sciences launched as an independent CDMO focused on oral solid dosage development and manufacturing in the U.S. The company offers formulation development, clinical manufacturing, and commercial production services. Its two cGMP facilities strengthen manufacturing capacity for oral solid dosage products. (Source: businesswire.com)
- February 2026: Piramal Pharma Solutions introduced its commercial tablet-in-capsule technology for oral solid dosage manufacturing. The new capability supports dual-release and combination drug formulations in a single capsule. It expands the company's advanced oral drug manufacturing services and provides greater flexibility for pharmaceutical developers. (Source: prnewswire.com)
Future of Oral Solid Dosage Contract Manufacturing Market
The oral solid dosage contract manufacturing market is expected to grow steadily in the coming years. Outsourcing will remain important as drug makers seek flexible production support. Generic drug demand will continue to support OSD manufacturing. Complex formulations could open new opportunities for niche CDMOs. Moreover, companies are likely to increase regional manufacturing as part of their supply chain build-up. Strategic alliances between pharmaceutical companies and CDMOs are also likely to drive the growth of the market.
Research Methodology
The study uses primary and secondary research to assess market trends and growth. Secondary sources include company websites, industry reports, regulatory data, and government sources. The analysis covers product, mechanism, end user, and regional segments. Market estimates also consider industry developments, company activities, outsourcing trends, and demand patterns. Detailed data sources, assumptions, and forecast methods are provided in the full report methodology.
Oral Solid Dosage Contract Manufacturing Market Report Scope
| Report Attributes | Details |
| Market size value in 2025 | USD 10.07 billion |
| Market size value in 2026 | USD 10.99 billion |
| Revenue forecast in 2034 | USD 22.62 billion |
| CAGR | 9.4% from 2026 – 2034 |
| Base year | 2025 |
| Historical data | 2021 – 2024 |
| Forecast period | 2026 – 2034 |
| Quantitative units | Revenue in USD billion and CAGR from 2026 to 2034 |
| Segments covered |
|
| Regional scope |
|
| Competitive Landscape |
|
| Report Format |
|
| Customization | Report customization as per your requirements with respect to countries, region and segmentation. |
Source: Polaris Market Research Analysis
Oral Solid Dosage Contract Manufacturing Market FAQ's
key companies in Oral Solid Dosage Contract Manufacturing Market are Alkem Laboratories, Catalent, Inc., Dr. Reddy's Laboratories, Evonik Industries AG
Oral Solid Dosage Contract Manufacturing Market exhibiting the CAGR of 9.4% during the forecast period.
The Oral Solid Dosage Contract Manufacturing Market report covering key segments are product, mechanism, end-user, and region.
key driving factors in Oral Solid Dosage Contract Manufacturing Market are Advancements in drug delivery technology is projected to spur the product demand
The global oral solid dosage contract manufacturing market size is expected to reach USD 22.62 billion by 2034
Oral solid dosage contract manufacturing means outsourcing the production of tablets and capsules. It helps pharmaceutical companies manufacture medicines efficiently.
It includes tablets, capsules, powders, and granules. These are the most common oral medicines.
Companies outsource OSD manufacturing to reduce costs and save time. It also provides access to specialized manufacturing facilities.
CDMOs develop and manufacture pharmaceutical products for other companies. They support both drug development and commercial production.
Controlled-release dosage forms release medicine gradually over time. This helps provide longer-lasting treatment
Download Sample Report of Oral Solid Dosage Contract Manufacturing Market
Please fill out the form to request a customized copy of the research report.
